ArticleBMC cardiovascular disorders2025
Stress hyperglycemia ratio and mortality in critically ill patients with heart failure: a retrospective cohort study from the MIMIC-IV database.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe stress hyperglycemia ratio (SHR) was created to reduce the impact of long-term chronic glycemic factors on stress hyperglycemia, which is considered a reliable biomarker for adverse outcomes in intensive care patients. However, the relationship between SHR and the outcomes for critically ill patients with heart failure (HF) remains unclear.
methodsThis retrospective cohort study analyzed 1,438 critically ill patients with HF from the Medical Information Mart for Intensive Care IV (MIMIC-IV, v3.1) database (2008–2022). Patients were followed from ICU admission to death or 365days. SHR was calculated as admission glucose (mmol/L) / [1.59 × HbA1c (%) − 2.59]. Multivariable Cox regression with four adjustment levels evaluated the association between SHR and mortality. Restricted cubic splines assessed nonlinear relationships, and Kaplan-Meier methodology with log-rank tests analyzed survival patterns.
resultsIn the cohort, each 1-unit increase in SHR was associated with a 40% higher 30-day mortality risk (HR 1.40, 95% CI 1.20–1.63, P < 0.001) and a 31% higher 90-day mortality risk (HR 1.31, 95% CI 1.14–1.51, P < 0.001). Patient survival rates decreased significantly with higher SHR tertiles (P < 0.001), and restricted cubic spline analysis confirmed a linear relationship. Subgroup analyses confirmed the robustness of these links.
conclusionsElevated SHR is significantly associated with increased mortality in critically ill patients with HF, supporting its role as a valuable biomarker for risk stratification in this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.